Journals / Balkan Medical Journal / 2016 / Cilt: 33 - Sayı: 6

Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis

Pages
614–619
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When wild-type G/G and G/C+C/C genotypes are compared in terms of clinical characteristics, there is a significant difference between the average age and the duration of disease in AS patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints.
📊
Key Findings & Data:Aims: To investigate the relationship between the MIF gene -173 G/C single-nucleotide polymorphism (SNP) and AS.
💡
Conclusion & Impact:When wild-type G/G and G/C+C/C genotypes are compared in terms of clinical characteristics, there is a significant difference between the average age and the duration of disease in AS patients (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Macrophage migration inhibitory (MIF) factor is a regulatory cytokine that inhibits random immune cell migration. MIF gene promoter polymorphisms play a role in the progression of several inflammatory disorders. Aims: To investigate the relationship between the MIF gene -173 G/C single-nucleotide polymorphism (SNP) and AS. Study Design: Cross-sectional study. Methods: In this study, a total of 161 AS and 194 normal controls were recruited. The MIF gene -173 G/C SNP was analyzed by polymerase chain reaction using the restriction fragment length polymorphism method. Results: There was no significant difference between groups in terms of genotype distribution (p>0.05). When wild-type G/G and G/C+C/C genotypes are compared in terms of clinical characteristics, there is a significant difference between the average age and the duration of disease in AS patients (p

🔖

Cite This Article

TEKCAN, A., YİGİT, S., NURSAL, A. F., RÜSTEMOĞLU, A., GÜREL, Ç., İNANIR, A. (2022). Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis. Balkan Medical Journal, Cilt: 33 - Sayı: 6, 614–619. https://ajindex.com/articles/461251

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Daikh DI, Chen PP. Advances in managing ankylosing spondyli- tis. F1000Prime Rep 2014;6:78. [CrossRef] Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease patho- genesis. Appl Clin Genet 2014;7:105-15. [CrossRef] Yigit S, Inanir A, Tural S, Filiz B, Tekcan A. The effect of IL-4 and MTHFR gene variants in ankylosing spondylitis. Z Rheumatol 2015;1:60-6. [CrossRef] Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 2015;15:489. [CrossRef] Falvey JD, Bentley RW, Merriman TR, Hampton MB, Barclay ML, Gearry RB, et al. Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: an associa- tion study in New Zealand Caucasians and meta-analysis. World J Gastroenterol 2013;19:6656-64. [CrossRef] Renner P, Roger T, Calandra T. Macrophage migration inhibi- tory factor: gene polymorphisms and susceptibility to inflamma- tory diseases. Clin Infect Dis 2005;41:513-9. [CrossRef] Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 2010;20:34-9. [CrossRef] Park SH, Choe JY, Kim SK, Lee H, Castrejón I, Pincus T. Rou- tine assessment of Patient Index Data (RAPID3) and Bath An- kylosing Spondylitis Disease Activity Index (BASDAI) scores yield similar information in 85 Korean patients with Ankylos- ing Spondylitis seen in usual clinical care. J Clin Rheumatol 2015;21:300-4. [CrossRef] Makhija R, Kingsnorth A, Demaine A. Gene polymorphisms of the macrophage migration inhibitory factor and acute pancreati- tis. JOP 2007;8:289-95.
  2. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epi- demiologic Statistics for Public Health, Version. Availabe from: www.OpenEpi.com (accessed 2015/09/17). Donn RP, Shelley E, Ollier WE, Thomson W, British Pediatric Rheumatology Study Group. A novel 5'-flanking region poly- morphism of macrophage migration inhibitory factor is associ- ated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782-5. [CrossRef] Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhib- itory factor gene: positive association of a functional polymor- phism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2402-9. [CrossRef] Radstake TR, Sweep FC, Wel